TimeScale Financial’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

TimeScale Financial’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$4	–	678
2022 Q4	$4	Hold	1	–	–	﹤0.01%	592
2022 Q3	$0	Sell	1 -1	-50%	-$5	﹤0.01%	598
2022 Q2	$0	Buy	+2	New	+$11	﹤0.01%	582
2022 Q1	–	Hold	0	–	–	–	578
2021 Q4	–	Hold	0	–	–	–	562
2021 Q3	–	Hold	0	–	–	–	548
2021 Q2	–	Hold	0	–	–	–	578
2021 Q1	–	Hold	0	–	–	–	550
2020 Q4	–	Hold	0	–	–	–	501
2020 Q3	–	Hold	0	–	–	–	534
2020 Q2	–	Hold	0	–	–	–	495
2020 Q1	–	Hold	0	–	–	–	576
2019 Q4	–	Hold	0	–	–	–	572
2019 Q3	–	Hold	0	–	–	–	554
2019 Q2	–	Hold	0	–	–	–	538

Other funds holding NVIV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

TimeScale Financial's NVIV Position: Q1 2023 in Review

TimeScale Financial sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2023, closing a stake of 1 share — an estimated $4 sold.

TimeScale Financial first reported a position in NVIV in Q2 2022 and held it in 3 quarters. The position peaked at $4 in Q4 2022. 20 funds tracked by Wall St. Rank hold NVIV as of Q1 2023.

TimeScale Financial reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2023 after selling out during the quarter.
TimeScale Financial sold 1 InVivo Therapeutics Holdings Corp share in Q1 2023, an estimated $4.
TimeScale Financial first reported a position in InVivo Therapeutics Holdings Corp in Q2 2022 and held it in 3 quarters.
TimeScale Financial's InVivo Therapeutics Holdings Corp position peaked at $4 in Q4 2022.
20 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2023.

Based on TimeScale Financial's 13F filing for Q1 2023, filed 24 Apr 2023.